Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is N/A as of Tuesday, October 6, 2026.
DEBT TO EQUITY RATIO
N/A
Market Cap
$225.24M
Debt to Equity Ratio
0.21
TTM Avg
0.17
3Y Avg
0.14
5Y Avg
0.13
Market Cap
$231.37M
Debt to Equity Ratio
0.82
TTM Avg
1.12
3Y Avg
0.68
5Y Avg
0.49
Market Cap
$231.77M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$220.93M
Debt to Equity Ratio
0.15
TTM Avg
0.08
3Y Avg
0.14
5Y Avg
0.10
Market Cap
$235.08M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$235.66M
Debt to Equity Ratio
2.16
TTM Avg
6.63
3Y Avg
12.85
5Y Avg
7.19
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vogenx Inc. (VOGX) | $227.91M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.60M | 7.85 | 8.11 | 4.57 | 3.79 |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | 0.21 | 0.17 | 0.14 | 0.13 |
| MacroGenics, Inc. (MGNX)vs › | $231.37M | 0.82 | 1.12 | 0.68 | 0.49 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | 0.00 | 0.00 | 0.00 | 0.00 |
| InflaRx N.V. (IFRX)vs › | $232.72M | 0.01 | 0.01 | 0.01 | 0.01 |
| Profound Medical Corp. (PROF)vs › | $220.93M | 0.15 | 0.08 | 0.14 | 0.10 |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 0.00 | 0.00 | 0.00 | 0.00 |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.66M | 2.16 | 6.63 | 12.85 | 7.19 |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | 0.00 | 0.00 | 0.00 | 0.00 |
Debt/Equity
N/A
Current Ratio
N/A
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
